Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Pharmasset Cancels Hepatitis Drug Development

By Pharmaceutical Processing | April 20, 2009

PRINCETON, N.J. (AP) — Pharmasset Inc. said Monday it is ending development of its most advanced drug candidate, clevudine, over concerns of severe muscle weakness in hepatitis B patients. Pharmasset said it made the decision to end the late-stage Quash studies voluntarily, following discussions with an independent monitoring board and the Food and Drug Administration. The company is maintaining its focus on a separate hepatitis C program with its partner Roche. Both hepatitis B and C are liver conditions. The decision was made based on the rate of South Korean patients with muscle weakness, or myopathy, side effects. “Although the number of cases of myopathy in the Quash trials was low and the severity was mild, more severe reports from other trials and post marketing surveillance led us to believe the risk benefit ratio for clevudine was insufficient to continue development,” said Chief Medical Officer Dr. Michelle Berrey in a statement. Pharmasset said it will continue collecting safety data and monitoring patients after the study is discontinued, though it won’t submit the results to the FDA for approval. “While we are obviously disappointed with the outcome, we believe the decision to stop dosing is an appropriate one,” said Chief Executive Schaefer Price in a statement. With the loss of clevudine, the company’s next most advanced drug candidate is Racivir, an HIV treatment in midstage development. The developing hepatitis C treatment R7128 is set for midstage development.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE